
|Videos|April 23, 2022
Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy
Author(s)Sheryl Stevenson
Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland
5


























